Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11714777 | 0.83 | L3MBTL1 (0.71) | RAB9AL3MBTL1NPC1POLBMEN1 | |
| SCHEMBL11530550 | 0.83 | ALDH1A1 (0.61) | RAB9AL3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL7533415 | 0.81 | ALDH1A1 (0.65) | RAB9AL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL1512585 | 0.81 | MEN1 (0.62) | RAB9AL3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL11530824 | 0.80 | MEN1 (0.50) | RAB9AL3MBTL1NPC1POLBMEN1 | |
| SCHEMBL6846339 | 0.80 | CES1 (0.57) | RAB9AL3MBTL1NPC1POLBMEN1 | |
| SCHEMBL22649378 | 0.79 | ALDH1A1 (0.58) | RAB9AL3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL17690051 | 0.79 | ALDH1A1 (0.58) | RAB9AL3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL22633970 | 0.79 | ALDH1A1 (0.62) | RAB9AL3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL13154822 | 0.79 | ALDH1A1 (0.53) | RAB9AL3MBTL1NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3065778-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | Celgene Corporation (US) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015069711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20120115817-A1 | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES | EMS S.A. (BR) | 2012-05-10 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | RAB9A 2736/4885L3MBTL1 1693/4885NPC1 1874/4885 |
| US-20120115817-A1 | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES | TNF, PER2, CRY1 | RAB9A 3521/4885L3MBTL1 4882/4885NPC1 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.